Qiagen (0RLT) AI Stock Analysis

0 Followers

Qiagen

(LSE:0RLT)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Recurring Consumables ModelThe high share of consumables and related revenue gives QIAGEN a recurring demand base tied to customers’ ongoing testing and research activity. This supports revenue visibility, creates workflow pull-through for instruments, and can make the business more resilient than one dependent mainly on episodic equipment sales.

Negative Factors

Transaction-Driven UncertaintySuspending guidance because of the pending transaction reduces visibility into near-term operating expectations and places execution within a changing ownership framework. Governance, capital allocation, and strategic priorities may shift before completion, creating uncertainty for employees, partners, and ongoing business planning.

Qiagen (0RLT) vs. iShares MSCI United Kingdom ETF (EWC)

Market Cap: EUR 10.39B
Dividend Yield: 5.16%
Average Volume (3M): 372.82K
Price to Earnings (P/E): 27.0
Beta (1Y): 0.47
Revenue Growth: -2.82%
EPS Growth: -9.29%
Country: UK
Employees: 5,400
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Diagnostics & Research

Qiagen Business Overview & Revenue Model

Company Description

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, man...

Qiagen Earnings Call Summary

Earnings Call Date:Aug 05, 2026(Q2-2026)|% Change Since:24.24%|Next Earnings Date:Feb 09, 2027

Earnings Call SentimentPositive

The call was broadly positive: management reported results above outlook for sales and adjusted EPS, strong cash generation, high profitability, and clear momentum in key growth pillars (Sample Technologies, QIAcuity, QDI) alongside active product launches and capital returns (40% dividend increase, $500M repurchase). Challenges include declines in QIAstat and PCR product groups, China and regional softness, a notable revenue loss from reduced immigration testing (~$35M) affecting QuantiFERON comparisons, modest margin and inventory pressures, and ongoing strategic/leadership transition that creates near-term uncertainty. On balance, the company emphasized confidence in a stronger second half of 2026 driven by new product rollouts and easing comparables.

Positive Updates

Beat on Sales and EPS

Net sales of $535 million, unchanged year-over-year and at CER, ahead of outlook for ~2% decline at CER; adjusted diluted EPS of $0.62 (reported and at CER) above outlook of at least $0.60 at CER.

Negative Updates

QIAstat Revenue Decline

QIAstat-Dx sales declined 7% at CER, driven by lower respiratory panel sales against a challenging prior-year comparison despite growth in gastrointestinal and meningitis/encephalitis panels.

Company Guidance

Qiagen reaffirmed 2026 guidance: full‑year net sales growth of about 1–2% at constant exchange rates (CER) and adjusted diluted EPS of at least $2.43 at CER, with Q3 guidance of ~1–2% CER sales growth and adjusted diluted EPS of at least $0.62 at CER. Management expects CER growth to accelerate from –1% in H1 to ~3–4% in H2 (a ~4–5 percentage‑point sequential improvement) with ~47% of sales in H1 and ~53% in H2; drivers cited include ~2 percentage points from the removal of NeuMoDx/DIALUNOX headwinds, ~2 percentage points from new Sample Tech systems and launches, and ~0.5 percentage point from Parse and modest U.S. life‑science recovery, while QuantiFERON is being tracked toward a $500 million 2026 target. The outlook already includes a tariff‑repayment benefit of about $0.02 EPS at CER (net of customer refunds), and assumes a ~1 percentage‑point FX tailwind to full‑year sales (neutral on EPS) but a ~1 percentage‑point FX headwind to Q3 sales (neutral on EPS).

Qiagen Risk Analysis

Qiagen disclosed 38 risk factors in its most recent earnings report. Qiagen reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Qiagen Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

GB:0RLT against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TMO	77Outperform	$266.10B	37.79	13.31%	0.26%	8.27%	9.59%
ILMN	76Outperform	$32.49B	36.15	31.45%	―	6.00%	31.48%
A	74Outperform	$50.15B	34.76	20.47%	0.58%	8.60%	19.07%
RVTY	74Outperform	$17.75B	70.02	3.50%	0.18%	4.56%	13.22%
DHR	73Outperform	$166.11B	38.45	8.18%	0.65%	5.52%	25.53%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

GB:0RLT and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
GB:0RLT	Qiagen	45.37	7.16	18.75%
A	Agilent Technologies	176.95	31.16	21.37%
DHR	Danaher Corporation	235.31	15.73	7.16%
ILMN	Illumina	212.93	93.00	77.55%
RVTY	Revvity, Inc.	158.25	65.08	69.85%
TMO	Thermo Fisher Scientific	717.71	139.61	24.15%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Qiagen AI Stock Analysis